Recent Finacing
Recent Raise
Inbiomotion, an IRB Barcelona/ICREA spin‑off, develops validated predictive diagnostics (MAF/Osteomet) to stratify breast and prostate cancer patients for bone metastasis risk and adjuvant bisphosphonate therapy, pursuing regulatory approval.
